 The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc NYSE: GSK and Vir Biotechnology Incs NASDAQ: VIR COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude. 